Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX HELSINKI LTD.  >  Orion Oyj    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Composition of the Nomination Committee of Orion Corporation

10/21/2020 | 11:40am EST

ORION CORPORATION     STOCK EXCHANGE RELEASE   21 OCTOBER 2020 at 6.40  p.m. EEST

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:

  • Annika Ekman
  • Petteri Karttunen
  • Timo Maasilta
  • Mikael Silvennoinen
  • Heikki Westerlund
  • Jukka Ylppö

Heikki Westerlund was elected Chairman of the Committee.  


The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.


The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at http://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/, a page in the Corporate Governance section of the Orion Group internet website.

  
Orion Corporation

Timo Lappalainen
President and CEO
   Olli Huotari
SVP, Corporate Functions
 

                                                                       
Contact person:
Timo Lappalainen, President and CEO
tel. +358 10 426 3692

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

 

Primary Logo


© GlobeNewswire 2020
All news about ORION OYJ
04:00aORION OYJ : publishes Financial Statement Release for 2020 on Tuesday 9 February..
AQ
01/18ORION OYJ : Animal Health and Vetoquinol expand collaboration – Vetoquinol..
AQ
01/12ORION OYJ : Recommendation by the Nomination Committee concerning the Board of D..
AQ
2020NUVO PHARMACEUTICALS INC : . - Miravo Healthcare Ireland Enters into Suvexx Lice..
AQ
2020ORION OYJ : 8,242 Orion Corporation A shares converted into B shares
AQ
2020ORION OYJ : invests EUR 17 million in its production plants in Turku
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
AQ
2020Prosecutor pressed charges against a member of Orion's Board of Directors for..
GL
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
PU
More news
Financials
Sales 2020 1 087 M 1 316 M 1 316 M
Net income 2020 236 M 286 M 286 M
Net cash 2020 135 M 164 M 164 M
P/E ratio 2020 23,3x
Yield 2020 3,83%
Capitalization 5 446 M 6 588 M 6 596 M
EV / Sales 2020 4,89x
EV / Sales 2021 5,00x
Nbr of Employees 3 320
Free-Float 86,5%
Chart ORION OYJ
Duration : Period :
Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener
Technical analysis trends ORION OYJ
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 33,78 €
Last Close Price 38,76 €
Spread / Highest target 8,36%
Spread / Average Target -12,8%
Spread / Lowest Target -27,8%
EPS Revisions
Managers and Directors
NameTitle
Timo Antero Lappalainen President & Chief Executive Officer
Satu Maarit Ahomäki Senior Vice President-Commercial Operations
Jari Ilmari Karlson Chief Financial Officer & SVP-Animal Health
Sinikka Markkula Chief Information Officer
Minna Ruotsalainen Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ORION OYJ4.64%6 679
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160